Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -64.72% is 155% below its 5-year average of -25.39%, near the low end of its 5-year range (-66.35%–41.99%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.38% below its 12-month average of -56.58%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -64.72%.
RETURN ON INVESTED CAPITAL (ROIC)
-64.72%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-56.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-19.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-25.39%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-25.70%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-14.38%
CURRENT VS 3Y AVG
-235.39%
CURRENT VS 5Y AVG
-154.89%
CURRENT VS 10Y AVG
-151.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
-81.49%
vs the sector median at left
Voyager Therapeutics, Inc.
Market Cap
$148.64M
Return on Invested Capital (ROIC)
-64.72%
TTM Avg
-56.58%
3Y Avg
-19.30%
5Y Avg
-25.39%
Market Cap
$148.73M
Return on Invested Capital (ROIC)
-134.15%
TTM Avg
-47.87%
3Y Avg
-96.96%
5Y Avg
-96.99%
Market Cap
$148.27M
Return on Invested Capital (ROIC)
-27.25%
TTM Avg
-49.08%
3Y Avg
-43.31%
5Y Avg
-52.54%
Market Cap
$149.36M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$146.62M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
Market Cap
$146.28M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$146.27M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-101.00%
3Y Avg
-120.85%
5Y Avg
-96.47%
Market Cap
$151.01M
Return on Invested Capital (ROIC)
-165.56%
TTM Avg
-176.54%
3Y Avg
-127.81%
5Y Avg
-112.12%
Market Cap
$152.72M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | $148.64M | -64.72% | -56.58% | -19.30% | -25.39% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -134.15% | -47.87% | -96.96% | -96.99% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -27.25% | -49.08% | -43.31% | -52.54% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -56.53% | -185.89% | -125.01% | -88.85% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -118.67% | -87.91% | -55.09% | -41.64% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -23.41% | -38.99% | -40.72% | -30.95% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | -10.85% | -101.00% | -120.85% | -96.47% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -165.56% | -176.54% | -127.81% | -112.12% |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | -223.90% | -825.42% | -606.12% | -416.73% |
ROIC
-64.7%
ROE
-69.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -64.72% |
| 2026-03-31 | -63.12% |
| 2025-12-31 | -58.41% |
| 2025-09-30 | -53.79% |
| 2025-06-30 | -42.88% |
| 2025-03-31 | -32.52% |
| 2024-12-31 | -24.26% |
| 2024-09-30 | 2.30% |
| 2024-06-30 | -1.51% |
| 2024-03-31 | -4.30% |
| 2023-12-31 | 41.99% |
| 2023-09-30 | 18.29% |
| 2023-06-30 | 32.07% |
| 2023-03-31 | 29.31% |
| 2022-12-31 | -56.74% |
| 2022-09-30 | -18.83% |
| 2022-06-30 | -66.35% |
| 2022-03-31 | -56.63% |
| 2021-12-31 | -51.53% |
| 2021-09-30 | -65.19% |
| 2021-06-30 | 3.60% |
| 2021-03-31 | 12.06% |
| 2020-12-31 | 11.66% |
| 2020-09-30 | 16.40% |
| 2020-06-30 | -28.27% |
| 2020-03-31 | -18.72% |
| 2019-12-31 | -18.54% |
| 2019-09-30 | -20.63% |
| 2019-06-30 | -20.16% |
| 2019-03-31 | -28.16% |
| 2018-12-31 | -62.67% |
| 2018-09-30 | -48.06% |
| 2018-06-30 | -44.45% |
| 2018-03-31 | -36.96% |
| 2017-12-31 | -42.63% |
| 2017-09-30 | -61.14% |
| 2017-06-30 | -41.19% |
| 2017-03-31 | -31.31% |
| 2016-12-31 | -23.50% |
| 2016-09-30 | -19.11% |
| 2016-06-30 | -15.02% |
| 2016-03-31 | -11.63% |
| 2015-12-31 | -9.85% |
| 2015-09-30 | -12.10% |
| 2015-06-30 | -11.23% |
| 2015-03-31 | -16.53% |
| 2014-12-31 | -159.23% |
